OPR - Delayed Quote USD

ZLAB Sep 2024 17.500 call (ZLAB240920C00017500)

3.4000

0.0000

(0.00%)

At close: March 21 at 11:34 AM EDT

Key Events

Loading Chart for ZLAB240920C00017500

9/21 12:03 PM

DELL

Previous Close 3.4000
Open --
Bid 0.8500
Ask 2.9500
Strike 17.50
Expire Date 2024-09-20
Day's Range 3.4000 - 3.4000
Contract Range --
Volume --
Open Interest 2

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024

Zai Lab Statement on Executive Management Team’s Agreement on Share Activities

Zai Lab Statement on Executive Management Team’s Agreement on Share Activities

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago

Shareholders in Zai Lab (NASDAQ:ZLAB) are in the red if they invested three years ago

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...

Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer

Shhh! 7 Small-Cap Stocks That Can Double by 2025

Shhh! 7 Small-Cap Stocks That Can Double by 2025

Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB)

Chief Legal Officer Edmondson Frazor Titus III Sells 10,000 Shares of Zai Lab Ltd (ZLAB)

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)

Zai Lab Announces Participation in March Investor Conference

Zai Lab Announces Participation in March Investor Conference

Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript